Ready. Raise. Rise. Campaign

Bristol-Myers SquibbThe Ready. Raise. Rise. campaign encourages everyone to raise and share a flag to salute those who have been touched by cancer, especially patients and caregivers, and learn more about a rapidly evolving area of research, Immuno-Oncology, which seeks to harness the body's own immune system to fight cancer. For the campaign’s second year, Eric Stonestreet of television's hit comedy "Modern Family" and films "Confirmation" and "The Secret Life of Pets" is joined by his mother Jamey, who faced and survived cancer twice. Bristol-Myers Squibb sponsors the campaign, which inspired people to raise more than 50,000 flags last year, and this year will make charitable donations to 23 participating cancer support groups on behalf of flag raisers.

"My mom has survived cancer twice, so I have personal reasons for standing with Ready. Raise. Rise. again this year - It gives me a chance to say how much I admire heroes like her, and at the same time it allows me to learn about promising research in the fight against cancer, like Immuno-Oncology. And participating in the campaign also supports cancer advocacy groups that are helping others like my mom," said Eric Stonestreet. "So mom and I are asking you to be Ready to Raise a virtual flag and Rise in celebration of patients, caregivers and anyone else you know whose life is touched by cancer."

With more than 32 million people living with cancer worldwide, nearly every family is impacted by cancer. Stonestreet is asking people to go to ReadyRaiseRise.com to create and share a flag in honor of someone who has been affected by cancer - whether it be themselves, a loved one or a caregiver. Each person who raises a flag can select one of 23 cancer advocacy organizations they wish to support and share their flag on social media using the hashtag #RaiseYourFlag. For each flag raised and shared, the selected organization will receive a charitable donation from Bristol-Myers Squibb. The company will distribute up to a total of $150,000 in charitable donations across participating organizations. Both Stonestreet and his mother are featured in a public service announcement to further extend the reach of the educational information about Immuno-Oncology research.

"Immuno-Oncology is an innovative area of research that may be changing the way we approach cancer," said Sanjiv Agarwala, MD, chief of medical oncology and hematology at St. Luke's Cancer Center in Bethlehem, PA, and professor of medicine at Temple University School of Medicine in Philadelphia, PA. "I'm passionate about educating the cancer community about Immuno-Oncology research as it explores a different way to approach cancer treatment, and that may allow patients with advanced cancer the potential to lead longer lives."

"Ready. Raise. Rise. continues to resonate with the cancer community, further motivating us to relentlessly pursue Immuno-Oncology research and make a difference for patients," said Teresa Bitetti, senior vice president, U.S. Oncology, Bristol-Myers Squibb. "Our ultimate goal with Immuno-Oncology is to improve survival and quality of life for patients living with various types of cancer, and this program provides an inspiring platform to honor patients and caregivers in a meaningful way."

Immuno-Oncology at Bristol-Myers Squibb
Bristol-Myers Squibb is leading research in an innovative field of cancer research and treatment known as Immuno-Oncology, which involves agents whose primary mechanism is to work directly with the body’s immune system to fight cancer. The company is exploring a variety of compounds and immunotherapeutic approaches for patients with different types of cancer, including researching the potential of combining Immuno-Oncology agents that target different pathways in the treatment of cancer.

Bristol-Myers Squibb is committed to advancing the science of Immuno-Oncology, with the goal of changing survival expectations and the way patients live with cancer.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...